ACE and COVID-19: (570) patients hospitalized with COVID-19 and who took Angiotensin Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs) before hospital admission had a significantly lower risk of death (n = 39, 0.74%).